Key result
Catecholaminergic polymorphic ventricular tachycardia is an inherited disorder driven by RyR2 or CASQ2 mutations, for which novel antiarrhythmic drugs are needed due to occasional treatment failures.
This review highlights the molecular mechanisms underlying CPVT, focusing on RyR2 and CASQ2 mutations, and emphasizes the need for novel targeted antiarrhythmic therapies.
No takes yet. Share an insight, caveat, or question.
Underscores need for new CPVT therapies; leaves open targeted antiarrhythmic development in human studies.
Kontula et al. (2005) conducted a review in Catecholaminergic polymorphic ventricular tachycardia (CPVT). Catecholaminergic polymorphic ventricular tachycardia is an inherited disorder driven by RyR2 or CASQ2 mutations, for which novel antiarrhythmic drugs are needed due to occasional treatment failures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: